Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.

Grove J, Hu K, Farquhar MJ, Goodall M, Walker L, Jamshad M, Drummer HE, Bill RM, Balfe P, McKeating JA.

Wellcome Open Res. 2017 Sep 7;2:82. doi: 10.12688/wellcomeopenres.12058.1. eCollection 2017.

2.

The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry.

Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, Lecoeur C, Rubinstein E, Dubuisson J, Wychowski C, Cocquerel L.

BMC Microbiol. 2009 May 28;9:111. doi: 10.1186/1471-2180-9-111.

3.

Significance of palmitoylation of CD81 on its association with tetraspanin-enriched microdomains and mediating hepatitis C virus cell entry.

Zhu YZ, Luo Y, Cao MM, Liu Y, Liu XQ, Wang W, Wu DG, Guan M, Xu QQ, Ren H, Zhao P, Qi ZT.

Virology. 2012 Aug 1;429(2):112-23. doi: 10.1016/j.virol.2012.03.002. Epub 2012 May 4.

4.

The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3.

Yu J, Lee CY, Changou CA, Cedano-Prieto DM, Takada YK, Takada Y.

Biochem J. 2017 Feb 15;474(4):589-596. doi: 10.1042/BCJ20160998. Epub 2016 Dec 19.

PMID:
27993971
5.

Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection.

Montpellier C, Tews BA, Poitrimole J, Rocha-Perugini V, D'Arienzo V, Potel J, Zhang XA, Rubinstein E, Dubuisson J, Cocquerel L.

J Biol Chem. 2011 Apr 22;286(16):13954-65. doi: 10.1074/jbc.M111.220103. Epub 2011 Feb 22.

6.

A role for CD81 and hepatitis C virus in hepatoma mobility.

Brimacombe CL, Wilson GK, Hübscher SG, McKeating JA, Farquhar MJ.

Viruses. 2014 Mar 24;6(3):1454-72. doi: 10.3390/v6031454.

7.

The specificity of homomeric clustering of CD81 is mediated by its δ-loop.

Homsi Y, Lang T.

FEBS Open Bio. 2017 Jan 19;7(2):274-283. doi: 10.1002/2211-5463.12187. eCollection 2017 Feb.

8.

Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.

Bose M, Mullick R, Das S, Das S, Karande AA.

Virus Res. 2016 Sep 15;224:46-57. doi: 10.1016/j.virusres.2016.08.010. Epub 2016 Aug 26.

PMID:
27574733
10.

CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha.

Zhang S, Kodys K, Babcock GJ, Szabo G.

Hepatology. 2013 Sep;58(3):940-9. doi: 10.1002/hep.25827. Epub 2013 Jan 18.

11.

Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells.

Crotta S, Ronconi V, Ulivieri C, Baldari CT, Valiante NM, Abrignani S, Wack A.

Eur J Immunol. 2006 Apr;36(4):919-29. Erratum in: Eur J Immunol. 2006 May;36(5):1350. Valiente, Nicholas M [corrected to Valiante, Nicholas M].

12.

A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.

Harman C, Zhong L, Ma L, Liu P, Deng L, Zhao Z, Yan H, Struble E, Virata-Theimer ML, Zhang P.

J Virol. 2015 Jan;89(1):492-501. doi: 10.1128/JVI.01661-14. Epub 2014 Oct 22.

13.

Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain.

Yalaoui S, Zougbédé S, Charrin S, Silvie O, Arduise C, Farhati K, Boucheix C, Mazier D, Rubinstein E, Froissard P.

PLoS Pathog. 2008 Feb 29;4(2):e1000010. doi: 10.1371/journal.ppat.1000010.

14.

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL.

J Biol Chem. 2003 Oct 24;278(43):41624-30. Epub 2003 Aug 11.

15.

A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.

Fofana I, Xiao F, Thumann C, Turek M, Zona L, Tawar RG, Grunert F, Thompson J, Zeisel MB, Baumert TF.

PLoS One. 2013 May 21;8(5):e64221. doi: 10.1371/journal.pone.0064221. Print 2013.

16.

Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.

Alhammad Y, Gu J, Boo I, Harrison D, McCaffrey K, Vietheer PT, Edwards S, Quinn C, Coulibaly F, Poumbourios P, Drummer HE.

J Virol. 2015 Dec;89(24):12245-61. doi: 10.1128/JVI.02070-15. Epub 2015 Sep 16.

17.

The tetraspanin web revisited by super-resolution microscopy.

Zuidscherwoude M, Göttfert F, Dunlock VM, Figdor CG, van den Bogaart G, van Spriel AB.

Sci Rep. 2015 Jul 17;5:12201. doi: 10.1038/srep12201.

18.

Synthesis of 1-boraadamantaneamine derivatives with selective astrocyte vs C6 glioma antiproliferative activity. A novel class of anti-hepatitis C agents with potential to bind CD81.

Wagner CE, Mohler ML, Kang GS, Miller DD, Geisert EE, Chang YA, Fleischer EB, Shea KJ.

J Med Chem. 2003 Jul 3;46(14):2823-33.

PMID:
12825926
19.

Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells.

Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T, Abrignani S, Pinzani M.

J Biol Chem. 2005 Mar 25;280(12):11329-39. Epub 2004 Dec 16.

20.

Supplemental Content

Support Center